6 completed, 2 terminated. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Terminated 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow X4 Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function Mavorixafor - Hepatic Insufficiency | Phase 1 | Completed | X4 Pharmaceuticals | 39 | 2025-02-28 | 2026-07-15 |
| Drug-Drug Interaction Potential of Mavorixafor Mavorixafor, Carbamazepine, Efavirenz - Healthy Participants | Phase 1 | Completed | X4 Pharmaceuticals | 38 | 2025-02-18 | 2025-07-01 |
| A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Mavorixafor - Neutropenia | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 32 | 2021-10-16 | 2025-08-06 |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Mavorixafor, Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 1 | Completed | X4 Pharmaceuticals | 16 | 2020-04-30 | 2024-08-27 |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma X4P-001, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | X4 Pharmaceuticals | 9 | 2016-12-07 | 2022-12-29 |
| X4P-001 and Pembrolizumab in Patients With Advanced Melanoma X4P-001, Pembrolizumab - Melanoma | Phase 1 | Completed | X4 Pharmaceuticals | 16 | 2016-09-15 | 2020-07-07 |
| Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma X4P-001, axitinib - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 74 | 2016-04-27 | 2024-10-03 |
| A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers X4P-001 - Healthy | Phase 1 | Terminated | X4 Pharmaceuticals | 15 | 2016-01-12 | 2018-12-07 |
Carcinoma, Renal Cell (2) · Glycogen Storage Disease Id (1) · Hepatic Insufficiency (1) · Melanoma (1) · Neutropenia (1) · Waldenstrom Macroglobulinemia (1)
mavorixafor (8) · Axitinib (1) · Carbamazepine (1) · Nivolumab (1) · efavirenz (1) · ibrutinib (1) · pembrolizumab (1)
United States (8) · Greece (1) · South Korea (1)
Lu Gan, MD, PhD (2)
2019 (1)